Free Trial

LENZ Therapeutics Q1 2023 Earnings Report

LENZ Therapeutics logo
$23.49 -1.45 (-5.81%)
As of 02/21/2025 04:00 PM Eastern

LENZ Therapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

LENZ Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

LENZ Therapeutics Earnings Headlines

LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics: Time For A Pause
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat